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Background: The Yukon Choice stent has been evaluated in several randomized controlled trials before albeit to date there has been no trial 
exclusively enrolling patients with diabetes mellitus. The objective of the study was to assess non-inferiority of the polymer-free sirolimus-eluting 
Yukon Choice stent as compared to the polymer-based Taxus Liberté stent with regard to the primary endpoint in-stent late lumen loss at 9 months 
in patients with diabetes mellitus.
Methods: Patients with diabetes mellitus undergoing percutaneous coronary intervention for clinically significant de novo coronary artery stenosis 
were randomized (1:1) to receive either the polymer-free sirolimus-eluting Yukon Choice stent or the polymer-based paclitaxel-eluting Taxus Liberté 
stent.
Results: A total of 240 patients were randomized. Quantitative coronary angiography was available for 79% of patients. Mean in-stent late lumen 
loss was 0.63±0.62 mm for the Yukon Choice stent and 0.45±0.60 mm for the Taxus Liberté stent. Based on the prespecified margin, the Yukon 
Choice stent failed to show non-inferiority for the primary endpoint and superiority for the Taxus Liberté stent could be demonstrated (p=0.04). 
During follow-up, there were no significant differences between groups regarding death, myocardial infarction, stent thrombosis, target lesion 
revascularization, target vessel revascularization or non-target vessel revascularization.
Conclusions: The Taxus Liberté stent demonstrated superiority over the polymer-free sirolimus-eluting Yukon Choice stent system with regard to 
the primary endpoint in-stent late lumen loss in patients with diabetes mellitus after 9 months follow-up. Both stents showed comparable clinical 
efficacy and safety.
